GEMINI-1 and -2: Subgroup Analyses Consistent With Overall Safety and Efficacy Findings for DTG + 3TC in ART-Naive Adults at Wk 96

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Among patients initiating dual therapy, virologic suppression rates maintained regardless of stratification by age, sex, race, and baseline HIV-1 RNA level or CD4+ cell count.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: October 31, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings